TCTMD’s Top 10 Most Popular Stories for January 2018
A feature on sexual harassment in cardiology, a clopidogrel recall, a review of Lp(a) in CVD, and the publication of REPRISE III all made the list this month.
This month, a feature examining sexual harassment in the cardiology profession ran away with the top-story spot. Other stories spanned a wide range of topics including the role and prognostic value of Lp(a) in CVD; how and when to “de-escalate” dual antiplatelet therapy in ACS; a US Food and Drug Administration alert about clopidogrel tablets that might contain a statin instead; and the print publication of REPRISE III. Also on the list for January 2018: friends and colleagues of Steven Sedlis, MD, mourn the loss of a mentor and patient advocate.
Tales of workplace sexual harassment and inappropriate interview questions within cardiology hint that the halls of medicine have their own secrets.
A new review provides direction on everything from standardizing assay values to large-scale testing of new therapies that lower Lp(a) levels.
While guidelines suggest sticking to a more potent antiplatelet regimen for a year, physicians are faced with many real-world reasons to switch earlier.
The single lot being recalled was distributed nationwide and may contain simvastatin instead of clopidogrel.
The publication compares the first-generation mechanically expanded TAVR system to a first- and second-generation self-expanding device.
The report provides information on everything from how to start, add, or switch therapy to integrating palliative/hospice care.
Experts say a new analysis from CURRENT AS helps shed light on the timing of aortic valve replacement, particularly in patients without symptoms.
The findings “are going to fundamentally change the way we approach prevention,” the author says. But one expert calls for more data.
The prolific clinician-investigator was known for his leadership at the Manhattan VA Medical Center and a passion for social justice.